Objective: This study aims to investigate venous thromboembolism (VTE) risk in relation to age at menopause, age at menarche, parity, bilateral oophorectomy, and time since menopause, as well as any interaction with randomized hormone therapy (HT) assignment, among postmenopausal women.
C ardiovascular disease (CVD) is the leading cause of death among women in developed countries. 1 Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important contributor to CVD burden, 2, 3 with an incidence of about 1 per 1,000 person-years among postmenopausal women, 4 and leads to a fatal outcome for approximately 10% of cases. 5 Identifying women at high thrombotic risk is of great importance for CVD prevention.
Women are subjected to endogenous estrogen exposure, exogenous estrogen exposure, or both throughout lifeVfrom puberty to menopause but also after menopause. Exogenous estrogens, including hormonal contraceptives and postmenopausal hormone therapy (HT), have been shown to be related to thrombotic risk. 6<8 This association may depend on several factors, including route of estrogen administration, 9<14 estrogen dose, 12, 15 and formulation 16 and type of progestogens. 10, 11, 15, 17, 18 Whereas reproductive life characteristics have been related to arterial disease, 19<25 cancer, 26<28 and mortality, 23,29<34 indicators of lifetime endogenous estrogen exposure had been investigated less in relation to VTE in postmenopausal women, with conflicting reports. 35<39 In addition, data on the potential interaction of HT use with different reproductive life characteristics on postmenopausal VTE risk are quite limited. 39 The Women's Health Initiative (WHI) HT clinical trials provided the opportunity to investigate the association of VTE with age at menarche, age at menopause, parity, bilateral oophorectomy, and time since menopause, as well as any potential interaction of HT use with these characteristics, on VTE risk among postmenopausal women.
METHODS

Study population
The WHI HT clinical trials were designed to test the effects of postmenopausal HT on a variety of health outcomes among healthy postmenopausal women, as has been described in detail elsewhere. 2, 3, 40 Briefly, 27,347 postmenopausal women aged 50 to 79 yearsVincluding 16,608 women with an intact uterus at baseline who were randomly assigned to receive either 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate or matching placebo (E + P trial) and 10,739 hysterectomized women who were assigned to receive either 0.625 mg/day conjugated equine estrogens or placebo (E-alone trial)Vwere recruited from 40 US clinical centers between 1993 and 1998. Before treatment assignment, a 3-month washout period was required for women who were current HT users at the initial screening (E + P trial, n = 815; E-alone trial, n = 1,128). All women provided a written informed consent form at enrollment and completed a series of self-administered baseline questionnaires from which detailed data on sociodemographic factors, reproductive life characteristics, personal and family medical history, medication use, and lifestyle were collected. Systolic blood pressure, diastolic blood pressure, weight, and height were measured at baseline clinic visits. For the present analysis, women with a personal history of VTE at baseline (n = 312) were excluded, resulting in a cohort of 27,035 postmenopausal women.
Exposure assessment and baseline covariates
Menopause status was defined as either no vaginal bleeding for 12 months (6 mo for women older than 55 y old), hysterectomy more than 3 months before, or use of postmenopausal HT. HT use was defined at baseline, and a 3-month washout period was required for women using hormones at the initial screening. Age at menopause was defined as the age of last menstrual bleeding or use of postmenopausal HT. Menarche was defined as the first menstrual period, and parity was defined as the number of term pregnancies. Bilateral oophorectomy was defined as the removal of both ovaries. Age at menarche, age at menopause, parity, and bilateral oophorectomy were self-reported on baseline questionnaires. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared and analyzed as a continuous variable. Smoking status was studied in two categories (nonsmoking or current smoking), and total metabolic equivalent of task score was analyzed as a continuous variable based on reported physical activity. 41 Hypertension status was defined as high blood pressure measurement (systolic blood pressure Q140 mm Hg, diastolic blood pressure Q90 mm Hg, or both), current use of antihypertensive medication, or both. A woman was considered to have diabetes if she reported the use of an antidiabetic medication or had answered yes to the question, BDid a doctor ever say that you had sugar diabetes or high blood sugar when you were not pregnant?[ Hypercholesterolemia was defined as the use of lipid-lowering treatment. History of events at baseline was self-reported and consisted of cancer, stroke, transient ischemic attack, and coronary heart disease, including myocardial infarction, angina pectoris, coronary artery bypass, and percutaneous transluminal coronary angioplasty.
VTE event ascertainment
Participants were followed up for clinical events every 6 months and had an annual in-clinic visit. 2,3 VTE events were defined as DVT or PE that occurred between the randomization date and the end of treatment assignment (2002 for the E + P trial and 2004 for the E-alone trial). Each possible event was reviewed by a local physician and centrally adjudicated by a review of medical records. Diagnosis of DVT required documentation of a treating physician's diagnosis and positive findings on Doppler or duplex ultrasound, venogram, plethysmography, or isotope scan. PE was based on a hospital discharge summary with a diagnosis of PE and positive results on ventilation-perfusion lung scan, pulmonary angiogram, or CT. PE was also confirmed if signs and symptoms suggested PE in the presence of a documented DVT. VTE events were further classified as procedure-related if they occurred within 60 days of an invasive procedure or as nonYprocedure-related otherwise. This classification, which referred to codes 997.3 (respiratory complications resulting from a procedure) and 997.2 (phlebitis and thrombophlebitis during or resulting from a procedure) of the International Classification of Diseases version 10, was adjudicated by a local physician and centrally confirmed by a medical committee. During follow-up, 426 first VTE events were validated (317 DVT and 208 PE), including 294 nonYprocedure-related events (222 DVT and 144 PE). Thirty cases could not be classified as either procedurerelated or nonYprocedure-related VTE.
Each presented model met the proportional hazards assumption. The time-to-event for VTE event was the number of days from randomization to the first diagnosis. Otherwise, censoring time was the time from randomization to the earliest date of death, loss to follow-up, or end of treatment assignment. Potential interactions between each reproductive life characteristic and treatment assignment (ie, placebo or active treatment in the E + P trial or the E-alone trial) on VTE risk were systematically tested. Because no significant interaction was detected, we performed pooled analyses with adjustment for randomization status. Further adjustments included age, BMI, race, history of events, smoking status, total metabolic equivalent of task score, hormone use at baseline, and hormone use duration. The linearity of VTE associations with reproductive life characteristics was systematically assessed. When the linearity of the models had been confirmed, linear trend across the different categories of each reproductive life characteristic was tested. For models that deviated from linearity, nonlinear (U-shaped) relations were assessed with the use of quadratic terms in Cox proportional hazards models.
Primary analysis focused on overall first VTE, including both nonYprocedure-related and procedure-related events. Subgroup analyses were specifically conducted for nonYprocedure-related VTE. Cases of procedure-related VTE were thus censored as noncases at the time of event, and women with VTE that could not be classified were excluded from the analysis. Finally, stratified analyses were performed according to the type of events (DVT or PE). Table 1 shows the baseline general characteristics of 27,035 postmenopausal women with no history of VTE at baseline who were included in the present analysis. The mean (SD) follow-up was 6.2 (1.6) years. Women were, on average, 63.4 years old, and the mean BMI was 29.1 kg/m 2 . More than 50% of participants had one or more of the following comorbidities: diabetes, hypertension, hypercholesterolemia, personal history of cancer, or CVD. The mean age at menarche and menopause was 12.6 and 47.9 years, respectively, and the mean number of children among 90% of multiparous women was 3.2. About 25% of women had had bilateral oophorectomy at baseline. Table 2 shows the HRs and 95% CIs of the first VTE event in relation to HT assignment versus placebo by reproductive life characteristics. No interaction of these characteristics with treatment assignment on VTE risk was detected. Therefore, pooled analyses with adjustment for treatment assignment were performed to assess the risk of VTE by reproductive life characteristics. Table 3 shows the risk of the first VTE event by reproductive life characteristics. There were no significant associations of VTE with age at menarche, age at menopause, parity, baseline bilateral oophorectomy, or time since menopause. However, analyses restricted to nonYprocedure-related VTE showed a U-shaped relationship between age at menopause and thrombotic risk that persisted after multivariable analysis (P for quadratic association G 0.01; Table 4 ). Compared with women with age at menopause between 40 (Table 4 ). With participants with age at menarche of 11 years or younger used as the reference group, women who had their first periods between 12 and 14 years and those who had their first periods at 15 years or older had a similar VTE risk (HR [95% CI]: 1.0 [0.8-1.4] and 1.0 [0.7-1.6], respectively). Regarding parity, women with one child or two children, women with three or four children, and those with five or more children had VTE risk similar to Finally, stratified analysis on the presence of comorbidities at baseline led to similar results as those obtained in the overall population for both total VTE and nonYprocedurerelated events. 
RESULTS
DISCUSSION
To our knowledge, this is the first study to show a U-shaped association between age at menopause and the risk of nonYprocedure-related VTE among postmenopausal women who had never had a history of VTE. After adjustment for potential confounders, women who experienced menopause at 39 years or younger or at 56 years or older had increased thrombotic risk as compared with women with age at menopause between 40 and 49 years. In contrast, this study suggests that VTE had no association with age at menarche, parity, bilateral oophorectomy, or time since menopause. In addition, there was no apparent interaction of HT use with these reproductive life characteristics on VTE risk.
Reproductive life characteristics have been studied primarily in relation to coronary events and mortality, but few studies have investigated the association of VTE with markers of lifetime endogenous sex steroid hormones among postmenopausal women.
VTE risk by age at menopause has been assessed in four studies. 35,37<39 In the Heart and Estrogen/progestin Replacement Study, Grady et al 35 found that being older than 52 years at the last menstrual period was independently associated with a higher risk of VTE. Later, Simon et al 37 confirmed this result in a case-control study of idiopathic VTE. They showed that, independently of BMI, women with late menopause had a higher thrombotic risk than did women with normal menopause. 37 Our data showing an increased risk of nonYprocedurerelated VTE with older age at menopause are concordant with these previous results. More recently, early menopause, which had been consistently associated with coronary heart disease and stroke, 22, 31, 42 has been found to be independently related to increased thrombotic risk in postmenopausal women. 38 Our findings showing that early menopause was associated with increased VTE risk are in agreement with these latest findings. Finally, our data are consistent with the results of a recent study showing increased VTE risk among women with early and late menopause, even though that association missed statistical significance in their study. 39 Previous data regarding the relationship between parity and thrombotic risk among postmenopausal women are conflicting. Although two case-control studies found that high parity was associated with increased VTE risk independently of BMI, 36, 37 two recent cohorts supported our findings of no association. 38, 39 Similarly, results regarding the relationship between parity and arterial events have been inconclusive. 33,43<46 Research on the relationship between age at menarche and CVD has been limited. 23, 43, 47 Our data are the first to focus on the risk of VTE. Overall, early menarche seems to be deleterious for arterial events and mortality. 23,34,43,47<49 Investigations of the impact of surgical menopause on VTE risk have been limited. Two studies showed no significant associations of VTE with surgical menopause, 9, 39 as we reported here. Another epidemiological study of VTE reported increased thrombotic risk among women with bilateral oophorectomy, which was no longer statistically significant after adjusting for confounding variables, including BMI. 50 To our knowledge, time since menopause has not been previously investigated in relation to VTE risk; however, it was recently studied in relation to arterial disease, with a finding of no significant association with coronary heart disease or stroke. 51 Nevertheless, time since menopause has been positively related to cardiovascular risk factors 52 and all-cause mortality. 53 Finally, there are limited data available regarding potential interactions of HT use with the different reproductive life characteristics. One recent study concurred with our findings that the associations of HT use with incident VTE did not differ by parity and type of menopause. 39 In addition, there is evidence for an interaction of HT use with time since menopause on arterial disease among postmenopausal women. 54 However, the effect of HT use on VTE risk by time since menopause has not been investigated to date. 55, 56 The existence of an independent association between age at menopause and VTE risk among postmenopausal women does not prove causality. The association of early menopause with increased thrombotic risk could be partly explained by the specific characteristics and/or comorbidities of women who experienced premature menopause. Indeed, early menopause could reflect a general adverse health status 42 and could be the result of an accelerated aging process that would involve multiple tissues and organs, including ovaries. 31 This biological process would lead to premature cessation of ovarian activity and increased incidence of age-related pathologies, including arterial and venous diseases. 22 Under this hypothesis, the hormonal changes observed among women with early menopause would have no causal effect on the occurrence of VTE, but cessation of ovarian activity and increase in VTE incidence could both be consequences of an accelerated aging process among these women. On the other hand, increased VTE risk could also be attributable to direct biological mechanisms, including a prothrombotic state, decreased blood flow, and/or alteration of vessel wall. 57 In particular, older age at menopause involves a longer exposure to both endogenous estradiol and progesterone. It could be hypothesized that the presence of both estrogen and progesterone receptors on the venous wall 58 could underlie possible deleterious effects of long-term estrogen and/or progesterone exposure on blood flow, leading to venous damage. On the other hand, whether procoagulant mechanisms or hemostatic activation could also be implicated in the association of age at menopause with thrombotic risk remains unknown.
The WHI HT clinical trials have several strengths. The WHI is a large, geographically diverse, multiethnic US cohort of postmenopausal women for whom baseline data were collected by standardized procedures and included detailed questionnaires with information on many key reproductive life characteristics, as well as many potential confounding factors that could be included in statistical analysis. In particular, the general characteristics of women differed according to their age at menopause, but adjustment for these baseline factors, including BMI, did not modify the results. Finally, VTE events were carefully validated by a central adjudication committee using criteria focused on imaging procedures. Despite these strengths, the WHI study has some limitations that deserve consideration. 2, 3 For the present analysis, an important limitation pertains to the self-reported information on reproductive life characteristics that could lead to misclassification. Such misclassification is likely to be nondifferential and would lead to an underestimation of true relationships, which could explain the nonsignificant association of VTE with age at menarche or time since menopause. Another limitation is that reproductive life characteristics are only surrogate markers of lifetime endogenous estrogen exposure and may not reflect results derived from a direct measurement of endogenous sex steroid hormone levels in relation to VTE risk. In addition, these findings referred to postmenopausal women who agreed to participate in the WHI HT clinical trials, so the result needs to be cautiously extrapolated to the general population of postmenopausal women. Finally, stratified analyses included subgroups with a relatively low number of cases, especially for PE, resulting in low statistical power.
CONCLUSIONS
Early and late menopause could emerge as newly identified risk factors for VTE among postmenopausal women. Because VTE may cause significant disability, death, or both, identifying new risk factors could improve risk stratification and disease prevention, especially for populations at high thrombotic risk. Future research should address VTE risk in relation to specific endocrine profiles of women with early or late menopause to elucidate biological mechanisms that could be involved in these relationships. Furthermore, a possible implication is that women with premature menopause, who could be at high risk for VTE, should avoid oral estrogen therapy. Although observational studies have suggested that transdermal estrogen, with or without a progestogen, may be a safer option with respect to VTE risk, additional research is needed.
